Ban HE

Language: Spanish
References: 6
Page: 17-20
PDF size: 51.64 Kb.

ABSTRACT

Drug eluting stents have become a mainstream in the treatment of coronary heart disease. Implementation of this technology into medical practice has resulted in a dramatic reduction in restenosis rates and late loss, which in turn is reflected in a significant reduction in MACE events due predominantly to a reduction in the need of a new re-intervention in the treated vessel. Historical comparisons between surgical results and the recently published studies with drug eluting stents shows that survival free of major events and the need of new revascularization are about the same in both groups of patients.

REFERENCES

1. Serruys PW, Unger F, Sousa E, Jatene A, Bonnier H, Vander Brand M, Van Herweden LA, et al: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.

2. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martínez J, Voguel D. et al: Argentine randomized study: Coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30 day and one year follow-up results. J Am Coll Cardiol. 2001; 37: 51-58.

3. Sigwart U: Stent or Surgery Trial. Europe. Presentation. American College of Cardiology Meeting. Orlando Florida, 2001.

4. Morice MC, Serruys PW, Sousa E, Fajadet J, Ban Hayashi E, Perin M, Colombo A, et al: A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.

5. Moses J: Sirolimus-coated Bx Velocity balloon-expandable stent. Presentation. Transcatheter Cardiovascular Therapeutics. Washington, DC. 2002.

6. Colombo A: On behalf of the Taxus II Investigators. Taxus II. International Study. Six months results. Intent to treat analysis. Presentation. Transcatheter Cardiovascular Therapeutics. Washington, DC. 2002.